Methods of treating mild cognitive impairment (mci) and related disorders
AssigneeBuck Institute for Age Research
InventorsVarghese John, Dale E. Bredesen
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.
Claims44
A method of mitigating in a mammal one or more symptoms associated with mild cognitive impairment (MCI) associated with amyloid deposits in the brain, the method comprising administering to the mammal one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam, or a pharmaceutically acceptable salt thereof, or an analogue thereof or its pharmaceutically acceptable salt, in an amount sufficient to mitigate a symptom of said MCI.
2-6. (canceled)
20-23. (canceled)
(canceled)
(canceled)
A method of lessening the severity or delaying the progression of a disease characterized by amyloid deposits in the brain in a mammal, the method comprising administering to the mammal an effective amount or regime of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam, or its pharmaceutically acceptable salt, or an analog thereof or its pharmaceutically acceptable salt, thereby reducing the risk, lessening the severity, or delaying the progression or onset of the disease.
A method of reducing the risk or delaying the onset of a disease characterized by amyloid deposits in the brain in a mammal, the method comprising administering to the mammal an effective amount or regime of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam, or its pharmaceutically acceptable salt, or an analog thereof or its pharmaceutically acceptable salt, thereby reducing the risk, lessening the severity, or delaying the progression or onset of the disease.
34-39. (canceled)
44-45. (canceled)
47-53. (canceled)
55-59. (canceled)
(canceled)
64-68. (canceled)
A method of promoting the processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway, comprising contacting a cell expressing APP with a compound selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam or its pharmaceutically acceptable salt, or an analog thereof or its pharmaceutically acceptable salt, in an amount sufficient to increase the processing of APP by the non-amyloidogenic pathway.
Dependencies are inferred from the claim text.